Previewing Only: You cannot submit data from this form

Previewing at Level 1

🖨 🔸 🍢 🚞

REF ID1Cole, R. C., Morandi, F., Avenell, J., and Daniel, G. B. **Trans-splenic portal scintigraphy in normal dogs**Vet Radiol Ultrasound2005462146-52 State: Excluded, Level: Abstract Review

Save to finish later Submit Data

1. Does this article **POTENTIALLY apply** to any of our Key Questions?

O Potentially eligible

Ineligible--contains NO USEFUL INFORMATION

Ineligible--SAVE as a reference article/ SCAN references

Clear Selection

Save to finish later Submit Data

Form took 0.765625 seconds to render





Previewing at Level 2

REF ID1Cole, R. C., Morandi, F., Avenell, J., and Daniel, G. B. **Trans-splenic portal scintigraphy in normal dogs**Vet Radiol Ultrasound2005462146-52 State: Excluded, Level: Abstract Review

·	
Keywords:	Save to finish later Submit Data
No keywords available	
	1. No Abstract provided (check ONLY if the abstract is unavailable on
	screen).
Increase Font Size	Pull article
Desmana Fant Sine	
Decrease Font Size	Clear Selection
	3. Reason for exclusion (check ONE)
Abstract:	No useful information (does not apply to the key questions)
The purpose of this study was to (1) establish a technique for	
ultrasound-guided trans-splenic portal scintigraphy (TSPS)	Not English language
using 99mTcO4(-), (2) evaluate portal vein morphology, (3)	
compare the radiation exposures for TSPS vs. per-rectal	Includes only subject less than 18 years-old
portal scintigraphy (PRPS), and (4) compare the quality of	
numerical data from the TSPS vs. PRPS. Eight juvenile dogs	Review or Opinion piece, OR no original data
underwent PRPS and TSPS (minimum of 48h between	\sim
studies) after initial screening tests. PRPS was done	Review or opinion piece: PULL FOR REFERENCE SEARCHING
according to established protocol using 425 ± -36 MBq (mean	Clear Selection
+/- SD) of 99mTcO4(-). TSPS was done with the dogs in right	4. Inclusion criteria (choose ALL that apply)
lateral recumbency over the gamma camera. 99mTcO4(-) (57 +/- 13.9 MBg) was injected into the spleen 1-2s following	
initiation of the dynamic acquisition. The frame rate was 4	Key Question 2. What is the evidence that a PHE, delivered at
frames/s for 5 min. There was significantly lower radioactivity	different patient ages or different frequencies, is associated with
of 99mTcO4(-) given and significantly higher total counts	benefits (i.e. improved outcomes) compared to care without a PHE
recorded in the liver and heart during the TSPS compared	(e.g. usual care or opportunistic delivery of clinical preventive
with PRPS. The total counts for the TSPS and PRPS were	services)?
7120 + -4386 and $830 + -523$, respectively. Percent	
absorption from the spleen was 52.5 +/- 19.1% compared	Key Question 3. What is the evidence that a PHE, delivered at
with $9.2 \pm -5.7\%$ for the colon. Calculated transit time for the	different patient ages or different frequencies, is associated with harms
TSPS studies was 7 +/- 2.3s. In TSPS studies, the splenic	(i.e. worse outcomes) compared to care without a PHE (e.g. usual
and portal veins were clearly identified. Radiation exposure	care or opportunistic delivery of clinical preventive services)?
levels of the dogs were significantly lower following TSPS	
than after PRPS. TSPS appears superior to PRPS as a	Key Question 4. What system-based interventions improve the
method to image the portal venous system representing a	receipt or delivery of the PHE (e.g. cost sharing such as deductibles,
valid alternative diagnostic test for animals with suspected	provider reminders)?
portosystemic shunts.	*
	*
	*
Increase Font Size	*
Degrappe Fant Size	*
Decrease Font Size	*
	*
	*
	*
	*
	*
	*
	*
	*
	*
	*
	*
	*
	*
	*
	*
	*
	*
	Save to finish later Submit Data

Form took 0.625 seconds to render

Previewing Only: You cannot submit data from this form

Previewing at Level 3

🚔 🔸 🏲 🔂 🗎

REF ID1Cole, R. C., Morandi, F., Avenell, J., and Daniel, G. B. Trans-splenic portal scintigraphy in normal dogs Vet Radiol Ultrasound2005462146-52 State: Excluded, Level: Abstract Review
Save to finish later Submit Data
1. After reviewing the ENTIRE artcile, should this article be included in the review?
○ YES
NO
Clear Selection 2. Exclusion criteria. Check all that apply:
Not English language
No human data
Meeting abstractno full article for review
Includes ONLY subjects less than 18 year of age
Exposure is NOT the PHE (at least one group in the intervention must meet the minimu definition of the PHE)
Article focuses on specific preventive measures ONLY without mention of the global PHE
Clinical preventive services delivered only during opportunistic visit (e.g., illness or symptom-related visit) without mention of the PHE
Article does not apply to any of the key questions
No Original Data no useful information
No Original Data pull for reference check
No eligible comparison group (not pre-post, historical control, clinical trial, or concurrent cohort)
No eligible comparison group but article contains valuable qualitative information
Other State Stat
3. KEY QUESTIONS: (check all that apply)
Key Question 2: What is the evidence that a PHE, delivered at different patient ages or different frequencies, is associated with benefits (i.e. improved outcomes) compared to care without a PHE (e.g. usual care or opportunistic delivery of clinical preventive services)? GO TO question 4 and choose outcomes
Key Question 3: What is the evidence that a PHE, delivered at different patient ages or different frequencies, is associated with harms (i.e. worse outcomes) compared to care without a PHE (e.g. usual care or opportunistic delivery of clinical preventive services)? GO TO question 5 and choose outcomes
Key Question 4: What system-based interventions improve the receipt or delivery of the PHE (e.g. cost sharing such as deductibles, provider reminders)? See the "Minimum definition of the PHE"

4. Key Question 2 outcomes (choose all that apply):

a. Delivery of recommended clinical preventive services

b. Patient attitudes/perceptions (e.g. knowledge, satisfaction, trust, respect)

c. Behavioral outcomes (e.g. tobacco cessation, adherence)

d.	Proximal/intermediate clinic	al outcomes (e.	g. cholesterol lowering	a, disease management)

- e. Distal clinical outcomes (e.g. measurable clinical events such as death, myocardial infarction)
- f. Economic outcomes (cost savings, improved health care utilization)
- g. Public Health (e.g. .improvements in family and community health, communicable disease containment)

5. Key Question 3 outcomes (choose all that apply):

a. Delivery of non-recommended clinical preventive services

b. Patient attitudes/perceptions (e.g. worry/anxiety)

c. Behavioral outcomes (e.g. continuation of risky behaviors)

d. Proximal/intermediate clinical outcomes (e.g. complications from testing)

e. Distal clinical outcomes (e.g. measurable clinical events such as death)

f. Economic outcomes (induced costs, less efficient health care utilization)

g. Public Health (e.g. declines in family and community health)

DEFINITION OF THE PHE

The Periodic Health Evaluation (PHE) consists of one or more visits with a health care provider for the primary purpose of assessing a patient's overall health and risk factors for disease which may be prevented by early intervention. During the PHE, health care providers perform a history and risk assessment, followed by a physical exam. Based on the information gathered, patients may receive counseling, immunizations, lab testing or arrangements for other preventive health services during the evaluation. This opportunity may serve to improve intermediate and long-term patient outcomes and ultimately the public's health by appropriate clinical management of chronic conditions, patient education, and fostering the patient-provider relationship. The PHE has the potential to affect patient health and health care cost for the individual, the health care industry, and society as a whole.

Save to finish later Submit Data

Form took 0.671875 seconds to render

< 🕨 🔂 🛑

Previewing Only: You cannot submit data from this form

Previewing at Level 4

Refid: 1, Cole, R. C., Morandi, F., Avenell, J., and Daniel, G. B., Trans-splenic portal scintigraphy in normal dogs, *Vet Radiol Ultrasound*, 46(2), 2005, p.146-52 State: Excluded, Level: 2

Save to finish later Submit Data

1. Pull previous article on this study for methods description (fill in only if this applies).

₽

OPull reference #	

С	lear	Se	lection	

STUDY CHARACTERISTICS

₽

2.	What	is	the	study	design?
----	------	----	-----	-------	---------

Randomized	controlled trial
------------	------------------

- Controlled trial, non-randomized
- Concurrent cohort
- Historical comparison
- Pre-post comparison
- Other (specify)
- Not reported

Clear Selection

3. What are the years that the study was conducted?

If this infomation is not given please enter "NS" in each of the boxes below.

Year beginning		3
Year ending	199	₽
4. Length of study follow-up		
Months		3
Vears		2
Not specified		
Onot applicable (cross-section	al study)	

Clear Selection

5. What country(ies) was the study conducted in (choose all that apply).



Check all that apply about the study se	setting
---	---------

Urban

Suburban

Rural

unclear

HEALTH CARE DELIVERY STRUCTURE

Choose all that apply to STUDY RECRUITMENT

7. Health care delivery system site (check all that apply):

r. nearth care derivery system site (check an that apply).		
Physician office		
Solo practice		
Group practice		
Hospital outpatient clinic		
Academic practice		
Community health center		
Employee health clinic		
VA/other US DOD		
National health service clinic		
Family medicine practice		
Internal medicine practice		
Ob/gyn practice		
Specialty practice		
Housestaff clinic	_	
Other health care site	B	
Not specified		
Not applicable		
8. Non-health care site (check all that apply):		
Worksite		
Non-worksite community setting		
Health fair		
Public place (i.e., supermarket), specify:		₽
Other		₽
9. Health Plan (check all that apply):		
Commercial insurance		
Medicare		
Medicaid		
VA/ other DOD		

National health plan	
Staff model HMO	
Other managed care plan	
Employer health plan	
Other	
Not specified	
Not applicable	
10. Who are the subjects?	
Patients	
How many patient comparison groups?	₽
Health providers	
How many provider comparison groups?	₽
Both (when choosing this option fill out the number of comparison groups for providers ar but do not choose	d patients,

Clear Selection

STUDY ELIGIBILITY CRITERIA for PATIENTS

11. Age range		
Minimum		₽
Maximum		₽
Average		₽
Unclear		
12. Gender		
Male		
Female		
Both		
Clear Selection 13. Select one or more racial or e	ethnic groups	
American Indian or Alaska N	lative	
Asian		
Black or African American		
Native Hawaiian or Other Pa	acific Islander	
Latino/Hispanic		
White		
Not Specified		
Other		₽
Other		₽
14. Is the patient an employee?		

Yes

O No

Not apllicable

Clear Selection

15. Is the patient an executive?

Yes

🔵 No

Not Applicable

Clear Selection

16. Is the patient a dependant?

Yes

No

Not applicable

Clear Selection

17. Health insurance plan type (check all that apply)

Commercial insurance

Medicare

Medicaid

VA/other US DOD

National Health Insurance

Managed Care Plan

Staff Model HMO

Other managed care plan

Employer health plan

Not Specified

Other (specify)

18. Visit to practice required?

- Yes
- No

Not Specified

Clear Selection

19. Initial visit only?

- Yes
- 🔵 No

Not applicable

Clear Selection

20. Number of visits:

₽

Enlarge Shrink

21. Over what time period:

Enlarge Shrink

22. Specific health conditions (check all that apply):

Hypertension Diabetes mellitus Tobacco smoking Hyperlipidemia Obesity Renal disease COPD Coronary artery disease Cancer Not Specified Other Other

₽

₽

₽

₽

₽

₽

₽

₽

₽

₽

₽

₽

₽

₽

₽

₽

₽

₽

₽

Other	
Other	 P
Other	 ₽
Other	 ₽
Other	₽
Other	₽
Other	 ₽
Other	 ₽
Other	 B
Other	 P

STUDY ELIGIBILITY CRITERIA for PROVIDERS

23. Were there provider eligibility criteria?

Yes

O No

Clear Selection

24. Provider Type (check all that apply):

Internists		
General Internists		
Ostetricians/Gynecologists		
Family Practitioners		
General Practitioners		
Medical sub-specialist (physician	ר)	P
Other specialist		₽
Housestaff		
Fellows		
Medical students		
Physicians NOS		
Other physicians		₽
Nurses		
Nurse practitioners		
Physician assistants		
Health provider NOS		
Other health provider		₽
Office Staff		
Not specified		
Not Applicable		

Health Care Delivery Structure (includes health care delivery system site, non-health care site, and health plan). Click all that apply to PROVIDER ELIGIBILITY CRITERIA

OF	I loolth	00.00	dalivani	a) (at a m	0.40	(ah a al		+ 6 6 +	annh		
23.	nealin	care	delivery	system	sile	спеск	all	เกลเ	appiv	11.	

Physician office		
Solo practice		
Group practice		
Hospital outpatient clinic		
Academic practice		
Community health center		
Employee health clinic		
VA/other US DOD		
National health service clinic		
Family medicine practice		
Internal medicine practice		
Ob/gyn practice		
Specialty practice		
Other health care site	P	
Not specified		
Not applicable		
26. Non-health care site (check all that apply):		
Worksite		
Non-worksite community setting		
Health fair		
Public place (i.e., supermarket), specify:		₽
Other		₽
Not specified		
Not Applicable		
27. Health Plan (check all that apply):		
Commercial insurance		
Medicare		
Medicaid		
VA/ other DOD		
National health plan		
Staff model HMO		

Other managed care plan		
Employer health plan		
Other	6	
Not Specified		
Not Applicable		
28. Provider experience		
Number of years in training	6	₽
Number of years since training		3-
Number of years in practice	6	3-
Information not provided		

TARGET PATIENT POPULATION CHARACTERISTICS

complete for each group of subjects

29.

COMPARISON GROUP 1 (define)

Enlarge Shrink

How is the PHE defined in GROUP 1?

30. Frequency. check all that apply	
Periodic (define)	
Annual (define)	
Initial visit	
Pre-employment	
Employment exam	
Scheduled	
Unclear	
not applicable	
Usual care	

WHAT COMPONENTS WERE PART OF THE PHE FOR GROUP 1?

Minimum included: part of the defined PHE in the study.

May have included: defined in the articles as "may have occured"

31	Visit

- Minimum included
- May have included

History and risk assessment including:

•	0	
	Minimum included	May have included
32. Diet		
33. Physical activity		
34. Alcohol/Substance abuse		
35. Injury prevention		
36. Safe sexual practices		
37. Tobacco smoking		
38. Calcium intake		
39. Folic acid		
40. Sun exposure		
41. Oral health		
42. Polypharmacy		

Physical exam including:

	Minimum included	May have included
43. Blood pressure		
44. Height		
45. Weight		
46. Pulse		
47. Cardiac exam		
48. Pulmonary		
49. Abdominal		
50. Neurologic		
51. Breast		
52. Gynecologic		
53. Rectal		
54. Prostate		
55. Foot Exam		
56. Eye exam (fundoscopic)		

57. Physical excam not otherwise specified		
58. Other 1 (define below)		
59. Other 2 (define below)		
60. Other 3 (define below)		
61. Define: Other 1		
Enlarge Shrink		
62. Define: Other 2		
Enlarge Shrink		
63. Define: Other		
Enlarge Shrink		

Was any counseling given as a part of or as a result of the PHE for GROUP 1?

Part of PHE Result of PHE			
64. Diet	\bigcirc	\bigcirc	Clear
65. Physical activity	\bigcirc	\bigcirc	Clear
66. Alcohol/substance abuse	\bigcirc	\bigcirc	Clear
67. Injury prevention	\bigcirc	\bigcirc	Clear
68. Safe sexual practices	\bigcirc	\bigcirc	Clear
69. Smoking	\bigcirc	\bigcirc	Clear
70. Folic Acid	\bigcirc	\bigcirc	Clear
71. Sun exposure	\bigcirc	\bigcirc	Clear
72. Oral health	\bigcirc	\bigcirc	Clear
73. Polypharmacy	\bigcirc	\bigcirc	Clear
74. Unspecified counseling	\bigcirc	\bigcirc	Clear
75. Were any immunizations o	rdered or perf	formed as pa	art of the PHE for GROUP 1?
Yes			
No or not applicable			
Clear Selection			
	Specify	Pe 乱	erformed Ordered



Was any testing performed or ordered as a result of the PHE for GROUP 1?

	Performed	Ordered	k
79. Pap smear	\bigcirc	\bigcirc	Clear
80. GC/chyl screen	\bigcirc	\bigcirc	Clear
81. Audiometry	\bigcirc	\bigcirc	Clear
82. Vision testing	\bigcirc	\bigcirc	Clear
83. EKG	\bigcirc	\bigcirc	Clear
84. CXR	\bigcirc	\bigcirc	Clear
85. Mammography	\bigcirc	\bigcirc	Clear
86. Colon cancer screening	\bigcirc	\bigcirc	Clear
87. Sigmoidoscopy	\bigcirc	\bigcirc	Clear
88. Colonoscopy	\bigcirc	\bigcirc	Clear
89. Fecal occult blood	\bigcirc	\bigcirc	Clear
90. Bone mineral density testing	\bigcirc	\bigcirc	Clear
91. Glucose (lab)	\bigcirc	\bigcirc	Clear
92. Lipids (lab)	\bigcirc	\bigcirc	Clear
93. HgbA1C	\bigcirc	\bigcirc	Clear
94. CBC	\bigcirc	\bigcirc	Clear
95. Chem-7	\bigcirc	\bigcirc	Clear
96. PSA	\bigcirc	\bigcirc	Clear
97. U/A	\bigcirc	\bigcirc	Clear
98. TB	\bigcirc	\bigcirc	Clear
99. Other 1	\bigcirc	\bigcirc	Clear
100. Other 2	\bigcirc	\bigcirc	Clear
101. Other 3	\bigcirc	\bigcirc	Clear
102. Define Other 1 for labs			

Enlarge Shrink

103. Define other 2 for labs

Enlarge Shrink

104. Define Other 3 for labs

Enlarge Shrink

105.

Is the exposure to the PHE defined in the same way across groups?

Yes

O No

Clear Selection

DESCRIPTION OF THE INTERVENTION for GROUP 1

106. Was there an intervention outside of the PHE in the study?

Yes	
No	
Clear Selection	
107. Who was the target of the in	ntervention?
Providers/office staff	
Office Staff/administration	
Patients	
108. Who was the outcome mea	sured on?
Providers/office staff	
Office staff/administration	
Patients	
109. Interventions targeting prov	iders/office staff, check all that apply.
Chart-based reminder	
Computer-based reminder	
Provider detailing	
Financial incentives	
CME incentives	
Other	₽
110. Interventions targeting patie	ents, check all that apply.
Written material (e.g., letter	, invitation)
Reminder	
Phone call	
Incentive (gift)	
Financial incentive (change	in co-pay/deductible)

Financial incentive (offer free health care)	
Patient-held medical record	
Other	
111. Is the intervention the same across groups?	
◯ Yes	
◯ No	
Clear Selection	

GENERAL CHARACTERISTICS FOR GROUP 1

	Ν	%
112. Female	9	₽
113. American Indian or Alaska Native	6	B
114. Asian	G	₽
115. Black or African American	9	₽
116. Native Hawaiian or other Pacific Islander	G	G
117. Latino/Hispanic	₽	₽
118. White	6	G
119. Other	6	₽
120. Low socioeconoimic status	G	G
121. Rural	6	₽
122. Income (describe)		

₽

Enlarge Shrink

123. Define "Other" for Comparison Group 1

Enlarge Shrink

124. Define "low socioeconomic status" for Comparison Group 1

Enlarge Shrink

125. Define "rural" for Comparison Group 1

Enlarge Shrink

https://www.clinical-analytics.com/d2d/ul1/review.asp?mode=previewMode&articleid=6... 02/28/2006

CLINICAL CHARACTERISTICS FOR GROUP 1

	N	%
126. Age	<u>-</u>	9
127. Hypertension	5 -	₽
128. Diabetes mellitus	<u></u>	B
129. Tobacco smoking	B -	B
130. Hyperlipidemia	<u>_</u>	6
131. Obesity	₽	B
132. Renal disease	<u>-</u>	B -
133. COPD	₽	6
134. Coronary artery disease	<u>_</u>	9
135. Cancer	₽	6
136. Other	₽	B

137. Define "other" clinical condition for Comparison Group 1.

Enlarge Shrink

EMPLOYMENT/INSURANCE CHARACTERISTICS FOR GROUP 1

	Ν	%
138. Executive employee	6	6
139. Non-executive employee	₽	₽
140. Employee dependant	₽	₿-
141. Commercial insurance	₽	₽
142. Medicare	₽	₽
143. Medicaid	₽	6
144. VA/ other US DOD	₽	₽
145. National health insurance	₽	₽
146. Managed care plan	₽	₽
147. Staff model HMO	B	₽

https://www.clinical-analytics.com/d2d/ul1/review.asp?mode=previewMode&articleid=6... 02/28/2006

148. Other managed care plan			
149. Employer health plan	₽	₽	
150. Other health plan	₽	B	
151. Define other managed care plan for comparison group	1		
Enlarge Shrink			
152. Define other health plan for comparison group 1			
Enlarge Shrink			
153. Other information not captured in previous questions.			
Enlarge Shrink			
-	*****		
154. *****			

COMPARISON GROUP 2 (define)

Enlarge Shrink

How is the PHE defined in this study for GROUP 2?

155. Frequency. check all that apply	

Periodic (define)	₽
Annual (define)	₽
Initial visit	
Pre-employment	
Employment exam	
Scheduled	
Unclear	
Not applicable	
Usual care	

WHAT COMPONENTS WERE PART OF THE PHE FOR GROUP 2?

Minimum included: part of the defined PHE in the study.

May have included: defined in the articles as "may have occured"

156. Visit

Minimum included

May have included

History and risk assessment including:

	Minimum included	May have included
157. Diet		
158. Physical activity		
159. Alcohol/Substance abuse		
160. Injury prevention		
161. Safe sexual practices		
162. Tobacco smoking		
163. Calcium intake		
164. Folic acid		
165. Sun exposure		
166. Oral health		
167. Polypharmacy		

Physical ex	am including:
-------------	---------------

	Minimum included M	ay have included
168. Blood pressure		
169. Height		
170. Weight		
171. Pulse		
172. Cardiac exam		
173. Pulmonary		
174. Abdominal		
175. Neurologic		
176. Breast		
177. Gynecologic		
178. Rectal		
179. Prostate		
180. Foot Exam		
181. Eye exam (fundoscopic)		
182. Physical exam not otherwise specified		
183. Other 1 (define below)		
184. Other 2 (define below)		

185. Other 3 (define below)		
186. Define: Other 1		
Enlarge Shrink		
187. Define: Other 2		
Enlarge Shrink 188. Define: Other 3		
Enlarge Shrink		

Was any counseling given as a part of or as a result of the PHE for GROUP 2?

F	Part of PHE Re	esult of PH	ΗE			
189. Diet	\bigcirc	\bigcirc	Clear			
190. Physical activity	\bigcirc	\bigcirc	Clear			
191. Alcohol/substance abuse	\bigcirc	\bigcirc	Clear			
192. Injury prevention	\bigcirc	\bigcirc	Clear			
193. Safe sexual practices	\bigcirc	\bigcirc	Clear			
194. Smoking	\bigcirc	\bigcirc	Clear			
195. Folic Acid	\bigcirc	\bigcirc	Clear			
196. Sun exposure	\bigcirc	\bigcirc	Clear			
197. Oral health	\bigcirc	\bigcirc	Clear			
198. Polypharmacy	\bigcirc	\bigcirc	Clear			
199. Unspecified counseling	\bigcirc	\bigcirc	Clear			
200. Were any immunizations of	ordered or pe	rformed a	as part of	the PHE fo	or GROUP 2?	
Yes						
No or not applicable						
Clear Selection						
	Specify	Р	erformed	Ordered		
201. Immunization 1		B				
202. Immunization 2		₽				

Was any testing performed or ordered as a result of the PHE for GROUP 2?

https://www.clinical-analytics.com/d2d/ul1/review.asp?mode=previewMode&articleid=6... 02/28/2006

	Performed	Ordered	b		
204. Pap smear	\bigcirc	\bigcirc	Clear		
205. GC/chyl screen	\bigcirc	\bigcirc	Clear		
206. Audiometry	\bigcirc	\bigcirc	Clear		
207. Vision testing	\bigcirc	\bigcirc	Clear		
208. EKG	\bigcirc	\bigcirc	Clear		
209. CXR	\bigcirc	\bigcirc	Clear		
210. Mammography	\bigcirc	\bigcirc	Clear		
211. Colon cancer screening	\bigcirc	\bigcirc	Clear		
212. Sigmoidoscopy	\bigcirc	\bigcirc	Clear		
213. Colonoscopy	\bigcirc	\bigcirc	Clear		
214. Fecal occult blood	\bigcirc	\bigcirc	Clear		
215. Bone mineral density testing	\bigcirc	\bigcirc	Clear		
216. Glucose (lab)	\bigcirc	\bigcirc	Clear		
217. Lipids (lab)	\bigcirc	\bigcirc	Clear		
218. HgbA1C	\bigcirc	\bigcirc	Clear		
219. CBC	\bigcirc	\bigcirc	Clear		
220. Chem-7	\bigcirc	\bigcirc	Clear		
221. PSA	\bigcirc	\bigcirc	Clear		
222. U/A	\bigcirc	\bigcirc	Clear		
223. TB	\bigcirc	\bigcirc	Clear		
224. Other 1	\bigcirc	\bigcirc	Clear		
225. Other 2	\bigcirc	\bigcirc	Clear		
226. Other 3	\bigcirc	\bigcirc	Clear		
227. Define Other 1 for labs					

Enlarge Shrink 228. Define other 2 for labs


Enlarge Shrink 229. Define Other 3 for labs

Enlarge Shrink DESCRIPTION OF THE INTERVENTION for GROUP 2

https://www.clinical-analytics.com/d2d/ul1/review.asp?mode=previewMode&articleid=6... 02/28/2006

230. Was there an intervention outside of the PHE in the study?
Yes
No
Clear Selection 231. Who was the target of the intervention?
Providers/office staff
Office Staff/administration
Patients
232. Who was the outcome measured on?
Providers/office staff
Office staff/administration
Patients
233. Interventions targeting providers/office staff, check all that apply.
Chart-based reminder
Computer-based reminder
Provider detailing
Financial incentives
CME incentives
Other 🚱
234. Interventions targeting patients, check all that apply.
Written material (e.g., letter, invitation)
Reminder
Phone call
Incentive (gift)
Financial incentive (change in co-pay/deductible)
Financial incentive (offer free health care)
Patient-held medical record
Other Strength Contract Contra
GENERAL CHARACTERISTICS FOR GROUP 2

	Ν	%
235. Female	<u></u>	₽
236. American Indian or Alaska Native	₽	G-
237. Asian	₽	6
238. Black or African American	₽	6
239. Native Hawaiian or other Pacific Islander	₽	6
240. Latino/Hispanic	₽	B



Enlarge Shrink

246. Define "Other" for Comparison Group 2

Enlarge Shrink

247. Define "low socioeconomic status" for Comparison Group 2

Enlarge Shrink

248. Define "rural" for Comparison Group 2

Enlarge Shrink

CLINICAL CHARACTERISTICS FOR GROUP 2

	N	%
249. Age	₽	₽
250. Hypertension	₽	₽
251. Diabetes mellitus	₽	₽
252. Tobacco smoking	₽	₽
253. Hyperlipidemia	₽	₽
254. Obesity	₽	₽
255. Renal disease	₽	⊡
256. COPD	₽	₽
257. Coronary artery disease	₽	₽
258. Cancer	B	₽
259. Other	₽	₽
260. Define "other" clinical con	dition for Comparison Group 2.	

Enlarge Shrink

EMPLOYMENT/INSURANCE CHARACTERISTICS FOR GROUP 2

	Ν	%
261. Executive employee	₽	₽
262. Non-executive employee	₽	₽
263. Employee dependant	₽	₽
264. Commercial insurance	₽	₽
265. Medicare	₽	₽
266. Medicaid	₽	₽
267. VA/ other US DOD	₽	₽
268. National health insurance	₽	₽
269. Managed care plan	₽	₽
270. Staff model HMO	₽	₽
271. Other managed care plan	₽	₽
272. Employer health plan	₽	₽
273. Other health plan	₽	₽
274. Define other managed care plan	for comparison group 2	

Enlarge Shrink

275. Define other health plan for comparison group 2.

Enlarge Shrink

276. Other information not captured in previous questions.

Enlarge Shrink

COMPARISON GROUP 3 (define)

Enlarge Shrink

https://www.clinical-analytics.com/d2d/ul1/review.asp?mode=previewMode&articleid=6... 02/28/2006

How is the PHE defined in this study for GROUP 3?

278. Frequency. check all that apply

Periodic (define)	₽
Annual (define)	₽
Initial visit	
Pre-employment	
Employment exam	
Scheduled	
Unclear	
Not applicable	
Usual care	

WHAT COMPONENTS WERE PART OF THE PHE FOR GROUP 3?

Minimum included: part of the defined PHE in the study.

May have included: defined in the articles as "may have occured"

279. Visit

Minimum included		
May have included		
History and risk assessment inclu	uding:	
	Minimum included May ha	ave included
280. Diet		
281. Physical activity		
282. Alcohol/Substance abuse	•	
283. Injury prevention		
284. Safe sexual practices		
285. Tobacco smoking		
286. Calcium intake		
287. Folic acid		
288. Sun exposure		
289. Oral health		
290. Polypharmacy		
Physical exam including:		
	Minimum incl	uded May have included
291. Blood pressure		

292. Height	
293. Weight	
294. Pulse	
295. Cardiac exam	
296. Pulmonary	
297. Abdominal	
298. Neurologic	
299. Breast	
300. Gynecologic	
301. Rectal	
302. Prostate	
303. Foot Exam	
304. Eye exam (fundoscopic)	
305. Physical exam not otherwise specified	
306. Other 1 (define below)	
307. Other 2 (define below)	
308. Other 3 (define below)	
309. Define: Other 1	

Enlarge Shrink


310. Define: Other 2

Enlarge Shrink

311. Define: Other 3

Enlarge Shrink

Was any counseling given as a part of or as a result of the PHE for GROUP 3?



317. Smoking	\bigcirc	\bigcirc	Clear
318. Folic Acid	\bigcirc	\bigcirc	Clear
319. Sun exposure	\bigcirc	\bigcirc	Clear
320. Oral health	\bigcirc	\bigcirc	Clear
321. Polypharmacy	\bigcirc	\bigcirc	Clear
322. Unspecified counseling	\bigcirc	\bigcirc	Clear

323. Were any immunizations ordered or performed as part of the PHE for GROUP 3?

○Yes

No or not applicable

Clear Selection

	Specify	P	erformed C	Ordered
324. Immunization 1		₽		
325. Immunization 2		₽		
326. Immunization 3		₽		

Was any testing performed or ordered as a result of the PHE for GROUP 3?

	Performed C	Ordered	b
327. Pap smear	\bigcirc	\bigcirc	Clear
328. GC/chyl screen	\bigcirc	\bigcirc	Clear
329. Audiometry	\bigcirc	\bigcirc	Clear
330. Vision testing	\bigcirc	\bigcirc	Clear
331. EKG	\bigcirc	\bigcirc	Clear
332. CXR	\bigcirc	\bigcirc	Clear
333. Mammography	\bigcirc	\bigcirc	Clear
334. Colon cancer screening	\bigcirc	\bigcirc	Clear
335. Sigmoidoscopy	\bigcirc	\bigcirc	Clear
336. Colonoscopy	\bigcirc	\bigcirc	Clear
337. Fecal occult blood	\bigcirc	\bigcirc	Clear
338. Bone mineral density testing	g 🔘	\bigcirc	Clear
339. Glucose (lab)	\bigcirc	\bigcirc	Clear
340. Lipids (lab)	\bigcirc	\bigcirc	Clear
341. HgbA1C	\bigcirc	\bigcirc	Clear
342. CBC	\bigcirc	\bigcirc	Clear
343. Chem-7	\bigcirc	\bigcirc	Clear
344. PSA	\bigcirc	\bigcirc	Clear
345. U/A	\bigcirc	\bigcirc	Clear

346. TB	\bigcirc	\bigcirc	Clear
347. Other 1	\bigcirc	\bigcirc	Clear
348. Other 2	\bigcirc	\bigcirc	Clear
349. Other 3	\bigcirc	\bigcirc	Clear
350. Define Other 1 for labs			

Enlarge Shrink 351. Define other 2 for labs

Enlarge Shrink 352. Define Other 3 for labs

Enlarge Shrink

DESCRIPTION OF THE INTERVENTION FOR GROUP 3

353. Was there an intervention outside of the PHE in the study?

Yes	
No	
Clear Selection 354. Who was the target of the interven	ition?
Providers/office staff	
Office Staff/administration	
Patients	
355. Who was the outcome measured of	on?
Providers/office staff	
Office staff/administration	
Patients	
356. Interventions targeting providers/o	ffice staff, check all that apply.
Chart-based reminder	
Computer-based reminder	
Provider detailing	
Financial incentives	
CME incentives	
Other	₽
357. Interventions targeting patients, ch	neck all that apply.
Written material (e.g., letter, invitat	iion)

Reminder
Phone call
Incentive (gift)
Financial incentive (change in co-pay/deductible)
Financial incentive (offer free health care)
Patient-held medical record
Other

GENERAL CHARACTERISTICS FOR GROUP 3

	N	%	
358. Female	B		2
359. American Indian or Alaska Native	9	9	-
360. Asian	9	9	-
361. Black or African American	9	9	2
362. Native Hawaiian or other Pacific Islander	B	B	~
363. Latino/Hispanic	B	G-	-
364. White	B	B	-
365. Other	₽	6	-
366. Low socioeconoimic status	9	6	-
367. Rural	B		2
368. Income (describe)			

₽

Enlarge Shrink

369. Define "Other" for Comparison Group 3

Enlarge Shrink 370. Define "low socioeconomic status" for Comparison Group 3

Enlarge Shrink 371. Define "rural" for Comparison Group 3

Enlarge Shrink				
CLINICAL CHA	RACTERISTICS FOR	ROUP 3		
	Ν	%		
372. Age	₽		1	

https://www.clinical-analytics.com/d2d/ul1/review.asp?mode=previewMode&articleid=6... 02/28/2006

373. Hypertension	B -	3
374. Diabetes mellitus	₽	B
375. Tobacco smoking	⊡ -	3
376. Hyperlipidemia	₽	₽
377. Obesity	<u>_</u>	9
378. Renal disease	₽	₽
379. COPD	<u></u>	<u></u>
380. Coronary artery disease	B	9
381. Cancer	<u>_</u>	3
382. Other	₽	6
383. Define "other" clinical condition for Co	mparison Group 3.	

Enlarge Shrink

EMPLOYMENT/INSURANCE CHARACTERISTICS FOR GROUP 3

	Ν	%
384. Executive employee	<u></u>	<u></u>
385. Non-executive employee	₽	₽
386. Employee dependant	<u></u>	₽
387. Commercial insurance	B	₽
388. Medicare	<u></u>	₽
389. Medicaid	<u></u>	₽
390. VA/ other US DOD	<u>_</u>	₽
391. National health insurance	₽	₽
392. Managed care plan	<u></u>	₽
393. Staff model HMO	₽	₽
394. Other managed care plan	<u></u>	B
395. Employer health plan	₽	₽
396. Other health plan	₽	₽

397. Define other managed care plan for comparison group 3

Enlarge Shrink

398. Define other health plan for comparison group 3.

Enlarge Shrink399. Other information not captured in previous questions.

COMPARISON GROUP 4 (define)

Enlarge Shrink

How is the PHE defined in this study for GROUP 4?

401. Frequency. check all that apply

Periodic (define)	₽
Annual (define)	₽
Initial visit	
Pre-employment	
Employment exam	
Scheduled	
Unclear	
Not applicable	
Usual care	

WHAT COMPONENTS WERE PART OF THE PHE FOR GROUP 4?

Minimum included: part of the defined PHE in the study.

May have included: defined in the articles as "may have occured"

402. Visit



May have included

History and risk assessment including:

Minimum included	May have included
------------------	-------------------

403. Diet	
404. Physical activity	
405. Alcohol/Substance abuse	
406. Injury prevention	
407. Safe sexual practices	
408. Tobacco smoking	
409. Calcium intake	
410. Folic acid	
411. Sun exposure	
412. Oral health	
413. Polypharmacy	

Physical exam including:

Minimum included May have included

414. Blood pressure	
415. Height	
416. Weight	
417. Pulse	
418. Cardiac exam	
419. Pulmonary	
420. Abdominal	
421. Neurologic	
422. Breast	
423. Gynecologic	
424. Rectal	
425. Prostate	
426. Foot Exam	
427. Eye exam (fundoscopic)	
428. Physical exam not otherwise specified	
429. Other 1 (define below)	
430. Other 2 (define below)	
431. Other 3 (define below)	

432. Define: Other 1

Enlarge Shrink 433. Define: Other 2 Enlarge Shrink 434. Define: Other 3

Enlarge Shrink

Was any counseling given as a part of or as a result of the PHE for GROUP 4?

	Part of PHE Result of PHE		
435. Diet	\bigcirc	\bigcirc	Clear
436. Physical activity	\bigcirc	\bigcirc	Clear
437. Alcohol/substance abuse	\bigcirc	\bigcirc	Clear
438. Injury prevention	\bigcirc	\bigcirc	Clear
439. Safe sexual practices	\bigcirc	\bigcirc	Clear
440. Smoking	\bigcirc	\bigcirc	Clear
441. Folic Acid	\bigcirc	\bigcirc	Clear
442. Sun exposure	\bigcirc	\bigcirc	Clear
443. Oral health	\bigcirc	\bigcirc	Clear
444. Polypharmacy	\bigcirc	\bigcirc	Clear
445. Unspecified counseling	\bigcirc	\bigcirc	Clear

446. Were any immunizations ordered or performed as part of the PHE for GROUP 4?

\bigcirc	Yes
\smile	100

No or not applicable

Clear Selection

	Specify		Performed	Ordered
447. Immunization 1		₽		
448. Immunization 2		₽		
449. Immunization 3		₽		

Was any testing performed or ordered as a result of the PHE for GROUP 4?

	Performed Ordered		
450. Pap smear	\bigcirc	\bigcirc	Clear
451. GC/chyl screen	\bigcirc	\bigcirc	Clear
452. Audiometry	\bigcirc	\bigcirc	Clear
453. Vision testing	\bigcirc	\bigcirc	Clear
454. EKG	\bigcirc	\bigcirc	Clear
455. CXR	\bigcirc	\bigcirc	Clear

456. Mammography	\bigcirc	\bigcirc	Clear
457. Colon cancer screening	\bigcirc	\bigcirc	Clear
458. Sigmoidoscopy	\bigcirc	\bigcirc	Clear
459. Colonoscopy	\bigcirc	\bigcirc	Clear
460. Fecal occult blood	\bigcirc	\bigcirc	Clear
461. Bone mineral density testing	\bigcirc	\bigcirc	Clear
462. Glucose (lab)	\bigcirc	\bigcirc	Clear
463. Lipids (lab)	\bigcirc	\bigcirc	Clear
464. HgbA1C	\bigcirc	\bigcirc	Clear
465. CBC	\bigcirc	\bigcirc	Clear
466. Chem-7	\bigcirc	\bigcirc	Clear
467. PSA	\bigcirc	\bigcirc	Clear
468. U/A	\bigcirc	\bigcirc	Clear
469. TB	\bigcirc	\bigcirc	Clear
470. Other 1	\bigcirc	\bigcirc	Clear
471. Other 2	\bigcirc	\bigcirc	Clear
472. Other 3	\bigcirc	\bigcirc	Clear
473. Define Other 1 for labs			

Enlarge Shrink

474. Define other 2 for labs

Enlarge Shrink

475. Define Other 3 for labs

Enlarge Shrink

DESCRIPTION OF THE INTERVENTION FOR GROUP 4

476. Was there an intervention outside of the PHE in the study?

Yes

O No

Clear Selection

477. Who was the target of the intervention?

Providers/office staff

Office Staff/administration

Page	32	of	50	
------	----	----	----	--

Patients	
478. Who was the outcome measured on?	
Providers/office staff	
Office staff/administration	
Patients	
479. Interventions targeting providers/office staff, check all that apply.	
Chart-based reminder	
Computer-based reminder	
Provider detailing	
Financial incentives	
CME incentives	
Other 🚱	
480. Interventions targeting patients, check all that apply.	
Written material (e.g., letter, invitation)	
Reminder	
Phone call	
Incentive (gift)	
Financial incentive (change in co-pay/deductible)	
Financial incentive (offer free health care)	
Patient-held medical record	

GENERAL CHARACTERISTICS FOR GROUP 4

	Ν	%
481. Female	₽	₽
482. American Indian or Alaska Native	₽	₽
483. Asian	₽	G
484. Black or African American	₽	6
485. Native Hawaiian or other Pacific Islander	₽	G
486. Latino/Hispanic	₽	6
487. White	₽	G
488. Other	6	6
489. Low socioeconoimic status	₽	G
490. Rural	₽	6
491. Income (describe)		

Enlarge Shrink

492. Define "Other" for Comparison Group 4

Enlarge Shrink 493. Define "low socioeconomic status" for Comparison Group 4

Enlarge Shrink

494. Define "rural" for Comparison Group 4

Enlarge Shrink

CLINICAL CHARACTERISTICS FOR GROUP 4

	N	%
495. Age	₽	B
496. Hypertension	₽	B
497. Diabetes mellitus	₽	B
498. Tobacco smoking	6	B
499. Hyperlipidemia	₽	B
500. Obesity	6	B
501. Renal disease	₽	B
502. COPD	₽	₽
503. Coronary artery disease	6	B
504. Cancer	₽	₽
505. Other	G-	B

506. Define "other" clinical condition for Comparison Group 3.

Enlarge Shrink

EMPLOYMENT/INSURANCE CHARACTERISTICS FOR GROUP 4

	N	%
507. Executive employee	₽	₽
508. Non-executive employee	<u>_</u>	₽
509. Employee dependant	B -	₽
510. Commercial insurance	₽	₽

511. Medicare	₽	₽
512. Medicaid	₽	B
513. VA/ other US DOD	₽	B
514. National health insurance	₽	B
515. Managed care plan	₽	₽
516. Staff model HMO	₽	₽
517. Other managed care plan	₽	₽
518. Employer health plan	₽	₽
519. Other health plan	₽	9

520. Define other managed care plan for comparison group 4

Enlarge Shrink

521. Define other health plan for comparison group 4.

Enlarge Shrink

522. Other information not captured in previous questions.

Enlarge Shrink


523.

COMPARISON GROUP 5 (define)

Enlarge Shrink

How is the PHE defined in this study for GROUP 5?

524. Frequency. check all that apply



Scheduled
Unclear
Not applicable
Usual care

WHAT COMPONENTS WERE PART OF THE PHE FOR GROUP 5?

Minimum included: part of the defined PHE in the study.

May have included: defined in the articles as "may have occured"

525. Visit

525. VISIL			
Minimum included			
May have included			
History and risk assessment including	ng:		
Μ	linimum included	I May have inclu	ided
526. Diet			
527. Physical activity			
528. Alcohol/Substance abuse			
529. Injury prevention			
530. Safe sexual practices			
531. Tobacco smoking			
532. Calcium intake			
533. Folic acid			
534. Sun exposure			
535. Oral health			
536. Polypharmacy			
Physical exam including:			
	Minin	num included Ma	ay have included
537. Blood pressure			
538. Height			
539. Weight			
540. Pulse			
541. Cardiac exam			
542. Pulmonary			
543. Abdominal			
544. Neurologic			

545. Breast		
546. Gynecologic		
547. Rectal		
548. Prostate		
549. Foot Exam		
550. Eye exam (fundoscopic)		
551. Physical exam not otherwise specified		
552. Other 1 (define below)		
553. Other 2 (define below)		
554. Other 3 (define below)		
555. Define: Other 1		

Enlarge Shrink

556. Define: Other 2

Enlarge Shrink

557. Define: Other 3

Enlarge Shrink

Was any counseling given as a part of or as a result of the PHE for GROUP 5?

	Part of PHE Result of PHE		
558. Diet	\bigcirc	\bigcirc	Clear
559. Physical activity	\bigcirc	\bigcirc	Clear
560. Alcohol/substance abuse	\bigcirc	\bigcirc	Clear
561. Injury prevention	\bigcirc	\bigcirc	Clear
562. Safe sexual practices	\bigcirc	\bigcirc	Clear
563. Smoking	\bigcirc	\bigcirc	Clear
564. Folic Acid	\bigcirc	\bigcirc	Clear
565. Sun exposure	\bigcirc	\bigcirc	Clear
566. Oral health	\bigcirc	\bigcirc	Clear
567. Polypharmacy	\bigcirc	\bigcirc	Clear
568. Unspecified counseling	\bigcirc	\bigcirc	Clear

569. Were any immunizations ordered or performed as part of the PHE for GROUP 5?

Yes				
◯ No or not applica	ble			
Clear Selection				
	Specify	F	Performed	Ordered
570. Immunization 1		₽		
571. Immunization 2		₽		
572. Immunization 3		₽		

Was any testing performed or ordered as a result of the PHE for GROUP 5?

	Performed	Ordered	b
573. Pap smear	\bigcirc	\bigcirc	Clear
574. GC/chyl screen	\bigcirc	\bigcirc	Clear
575. Audiometry	\bigcirc	\bigcirc	Clear
576. Vision testing	\bigcirc	\bigcirc	Clear
577. EKG	\bigcirc	\bigcirc	Clear
578. CXR	\bigcirc	\bigcirc	Clear
579. Mammography	\bigcirc	\bigcirc	Clear
580. Colon cancer screening	\bigcirc	\bigcirc	Clear
581. Sigmoidoscopy	\bigcirc	\bigcirc	Clear
582. Colonoscopy	0	\bigcirc	Clear
583. Fecal occult blood		\bigcirc	Clear
584. Bone mineral density testing	\bigcirc	\bigcirc	Clear
585. Glucose (lab)	\bigcirc	\bigcirc	Clear
586. Lipids (lab)		\bigcirc	Clear
587. HgbA1C	\bigcirc	\bigcirc	Clear
588. CBC	\bigcirc	\bigcirc	Clear
589. Chem-7	\bigcirc	\bigcirc	Clear
590. PSA	\bigcirc	\bigcirc	Clear
591. U/A	\bigcirc	\bigcirc	Clear
592. TB	\bigcirc	\bigcirc	Clear
593. Other 1	\bigcirc	\bigcirc	Clear
594. Other 2	\bigcirc	\bigcirc	Clear
595. Other 3	\bigcirc	\bigcirc	Clear
596. Define Other 1 for labs			

Enlarge Shrink

597. Define other 2 for labs

Enlarge Shrink

598. Define Other 3 for labs

Enlarge Shrink

DESCRIPTION OF THE INTERVENTION FOR GROUP 5

599. Was there an intervention outside of the PHE in the study?

Yes
No
Clear Selection
600. Who was the target of the intervention?
Providers/office staff
Office Staff/administration
Patients
601. Who was the outcome measured on?
Providers/office staff
Office staff/administration
Patients
602. Interventions targeting providers/office staff, check all that apply.
Chart-based reminder
Computer-based reminder
Provider detailing
Financial incentives
CME incentives
Other 🚱
603. Interventions targeting patients, check all that apply.
Written material (e.g., letter, invitation)
Reminder
Phone call
Incentive (gift)
Financial incentive (change in co-pay/deductible)
Financial incentive (offer free health care)
Patient-held medical record
Other

GENERAL CHARACTERISTICS FOR GROUP 5

https://www.clinical-analytics.com/d2d/ul1/review.asp?mode=previewMode&articleid=6... 02/28/2006

₽

	Ν	%
604. Female	5	₽
605. American Indian or Alaska Native	<u></u>	₽
606. Asian	<u>.</u>	₽
607. Black or African American	₽	B
608. Native Hawaiian or other Pacific Islander	5	₽
609. Latino/Hispanic	9	₽
610. White	<u></u>	₽
611. Other	₽	₽
612. Low socioeconoimic status		₽
613. Rural	₽	B

614. Income (describe)

Enlarge Shrink

615. Define "Other" for Comparison Group 5

Enlarge Shrink

616. Define "low socioeconomic status" for Comparison Group 5

Enlarge Shrink

617. Define "rural" for Comparison Group 5

Enlarge Shrink

CLINICAL CHARACTERISTICS FOR GROUP 5

	Ν	%
618. Age	₽	₽
619. Hypertension	₽	6
620. Diabetes mellitus	₽	₽
621. Tobacco smoking	₽	G
622. Hyperlipidemia	₽	G
623. Obesity	₽	B
624. Renal disease	₽	6
625. COPD	₽	B
		2

626. Coronary artery disease		
627. Cancer	₽	B
628. Other	₽	•

629. Define "other" clinical condition for Comparison Group 5.

Enlarge Shrink

EMPLOYMENT/INSURANCE CHARACTERISTICS FOR GROUP 5

	Ν	%
630. Executive employee	₽	₽
631. Non-executive employee	6	6
632. Employee dependant	₽	6
633. Commercial insurance	6	6
634. Medicare	₽	G
635. Medicaid	6	6
636. VA/ other US DOD	₽	6
637. National health insurance	6	6
638. Managed care plan	G	G
639. Staff model HMO	6	5
640. Other managed care plan	B	G
641. Employer health plan	6	B
642. Other health plan	₽	6

643. Define other managed care plan for comparison group 5

Enlarge Shrink

644. Define other health plan for comparison group 5.

Enlarge Shrink

645. Other information not captured in previous questions.

Enlarge Shrink

TARGET PROVIDER POPULATION CHARACTERISTICS

646.

COMPARISON GROUP 1 (define)

Enlarge Shrink

GENERAL CHARACTERISTICS FOR PROVIDER GROUP 1

	Ν	%
647. Female	₽	₽
648. American Indian or Alaska Native	B	₽
649. Asian	<u></u>	G-
650. Black or African American	6	₽
651. Native Hawaiian or other Pacific Islander	₽	G
652. Latino/Hispanic	₽	6
653. White	<u></u>	G
654. Other	₽	G
655. Not specified	B	G-

656. Define "Other" for Comparison goup 1

Enlarge Shrink

GENERAL PHYSICIAN EXPERIENCE FOR GROUP 1

	Mean	Median	Range
657. Age	₽	₽	-
658. Number of years in training (housestaff and fellows)	₽	₽	₽
659. Years since training	₽	₽	₽
660. Number of years in practice.	G	<u>_</u>	6
CC4. Drastias active runk are used DUE dat	in an all Oliah all that an all t		

661. Practice setting; where was PHE delivered? Click all that apply

Physician office

Solo practice	
Group practice	
Hospital outpatient clinic	
Academic practice	
Community health center	
Employee health clinic	
VA/other US DOD	
National health service clinic	
Family medicine practice	
Internal medicine practice	
Ob/gyn practice	
Specialty practice	
Other health care site	₽
Worksite	
Non-work site community setting	
Health fair	
Public Place (specify)	₽
Commercial insurance	
Public insurance: Medicare	
Public insurance: Medicaid	
Public insurance: VA/ other US DOD	
National health insurance	
Managed care plan	
Staff model HMO	
Other managed care plan	₽
Employer health plan	
Other (specify)	₽
662.	
******	*****

COMPARISON GROUP 2 (define)

Enlarge Shrink 663.

GENERAL CHARACTERISTICS FOR PROVIDER GROUP 2

Not specified

O See below

Clear Selection



Enlarge Shrink

GENERAL PHYSICIAN EXPERIENCE FOR GROUP 2

	Mean	Median	Range
673. Age	3	₽	₽
674. Number of years in training (housestaff and fellows)	₽	₽	₽
675. Years since training	3	₽	₽
676. Number of years in practice.	B	₽	₽
677. Practice setting; where was PHE delivered? C	Click all that apply		
Physician office			
Solo practice			
Group practice			
Hospital outpatient clinic			
Academic practice			
Community health center			
Employee health clinic			
VA/other US DOD			
National health service clinic			

Family medicine practice	
Internal medicine practice	
Ob/gyn practice	
Specialty practice	
Other health care site	3 -
Worksite	
Non-work site community setting	
Health fair	
Public Place (specify)	B -
Commercial insurance	
Public insurance: Medicare	
Public insurance: Medicaid	
Public insurance: VA/ other US DOD	
National health insurance	
Managed care plan	
Staff model HMO	
Other managed care plan	₽
Employer health plan	
Other (specify)	₽
678.	
******	*****

COMPARISON GROUP 3 (define)

Enlarge Shrink 679.

GENERAL CHARACTERISTICS FOR PROVIDER GROUP 3



682. Asian	B	₽
683. Black or African American	B	₽
684. Native Hawaiian or other Pacific Islander	₽	₽
685. Latino/Hispanic	₽	₽
686. White	₽	₽
687. Other	₽	₽
688. Define "Other" for Comparison group 3		

Enlarge Shrink

GENERAL PHYSICIAN EXPERIENCE FOR GROUP 3

	Mean	Median	Range	
689. Age	5	P	₽	B
690. Number of years in training (housestaff and fellows)	3	k	₽	3
691. Years since training	5	k	₽	₽
692. Number of years in practice.	5	r	6	P
693. Practice setting; where was PHE de	livered? Click all that apply			
Physician office				
Solo practice				
Group practice				
Hospital outpatient clinic				
Academic practice				
Community health center				
Employee health clinic				
VA/other US DOD				
National health service clinic				
Family medicine practice				
Internal medicine practice				
Ob/gyn practice				
Specialty practice				
Other health care site		₽		
Worksite				
Non-work site community setting				

Health fair	
Public Place (specify)	B
Commercial insurance	
Public insurance: Medicare	
Public insurance: Medicaid	
Public insurance: VA/ other US DOD	
National health insurance	
Managed care plan	
Staff model HMO	
Other managed care plan	<u></u>
Employer health plan	
Other (specify)	<u></u>
694.	
*****	*****

COMPARISON GROUP 4 (define)

Enlarge Shrink 695.

GENERAL CHARACTERISTICS FOR PROVIDER GROUP 4

Not specified

O See below

Clear Selection

	Ν	%	
696. Female	6	2	ŀ
697. American Indian or Alaska Native	[3-	ŀ
698. Asian	6	₽0	ŀ
699. Black or African American		<u>}</u>	ŀ
700. Native Hawaiian or other Pacific Islander		<u>}</u>	ŀ
701. Latino/Hispanic		3	ŀ
702. White	6	3	ŀ
703. Other		3- 10	ŀ

704. Define "Other" for Comparison group 4

Enlarge Shrink

GENERAL PHYSICIAN EXPERIENCE FOR GROUP 4

	Mean	Median	Range	
705. Age	5	}	₽	₽
706. Number of years in training (housestaff and fellows)	٥	}	B	3
707. Years since training	5	}	₽	₽
708. Number of years in practice.	5	}	6	B
709. Practice setting; where was PHE delive	red? Click all that apply			
Physician office				
Solo practice				
Group practice				
Hospital outpatient clinic				
Academic practice				
Community health center				
Employee health clinic				
VA/other US DOD				
National health service clinic				
Family medicine practice				
Internal medicine practice				
Ob/gyn practice				
Specialty practice				
Other health care site		₽		
Worksite				
Non-work site community setting				
Health fair				
Public Place (specify)		₽		
Commercial insurance				
Public insurance: Medicare				
Public insurance: Medicaid				
Public insurance: VA/ other US DOD				
National health insurance				

*****	*****
710.	
Other (specify)	₽
Employer health plan	
Other managed care plan	B
Staff model HMO	
Managed care plan	

COMPARISON GROUP 5 (define)

Enlarge Shrink 711.

GENERAL CHARACTERISTICS FOR PROVIDER GROUP 5

Not specified

O See below

Clear Selection

	N	%
712. Female	B	₽
713. American Indian or Alaska Native	G	G-
714. Asian	B	₽
715. Black or African American	G	G
716. Native Hawaiian or other Pacific Islander	B	₽
717. Latino/Hispanic	G	G
718. White	6	₽
719. Other	G	Ŀ
720. Define "Other" for Comparison goup 5		

Enlarge Shrink

GENERAL PHYSICIAN EXPERIENCE FOR GROUP 5

https://www.clinical-analytics.com/d2d/ul1/review.asp?mode=previewMode&articleid=6... 02/28/2006

SRS Form

	Mean	Median	Ra	nge
721. Age		₽	₽	B -
722. Number of years in training (housestaff and fellows)		₽-	₽	6
723. Years since training		₽	₽	<u></u>
724. Number of years in practice.		₽	₽	B
725. Practice setting; where was PHE del	livered? Click all that apply	,		
Physician office				
Solo practice				
Group practice				
Hospital outpatient clinic				
Academic practice				
Community health center				
Employee health clinic				
VA/other US DOD				
National health service clinic				
Family medicine practice				
Internal medicine practice				
Ob/gyn practice				
Specialty practice				
Other health care site		₽		
Worksite				
Non-work site community setting				
Health fair				
Public Place (specify)		₽		
Commercial insurance				
Public insurance: Medicare				
Public insurance: Medicaid				
Public insurance: VA/ other US DOD)			
National health insurance				
Managed care plan				
Staff model HMO				
Other managed care plan		⊡ ≁		
Employer health plan				
Other (specify)		₿ ₽		

AUDITOR INFORMATION

this section IS NOT to be completed by reviewer #1

726. Auditor information	
Auditor Name	B-
Auditor review completion date	B-
727. Auditor Notes	
Enlarge Shrink	
Save to finish later Submit Data	

Form took 69.25 seconds to render

P 🔒

Previewing Only: You cannot submit data from this form

Previewing at Level 5

Refid: 1, Cole, R. C., Morandi, F., Avenell, J., and Daniel, G. B., Trans-splenic portal scintigraphy in normal dogs, *Vet Radiol Ultrasound*, 46(2), 2005, p.146-52 State: Excluded, Level: 2

Save to finish later Submit Data

STUDY DESIGN

1. What is the design of the study?

- Randomized controlled trial.
- Nonrandomized controlled trial
- Prospective cohort study with comparison group
- Retospective cohort study with comparison group
- Mixed prospective/retrospective cohort study with comparison group
- Case-control study
- Pre-post comparison study with comparison group
- Other

Clear Selection

STUDY POPULATION SELECTION

₽

2. How good was the randomization to treatment groups and how difficult would it have been to manipulate the randomization?

- Excellent ((centralized randomization scheme [randomized in different location than treatment] and study monitor)
- Good (centralized randomization scheme or study monitor but not both)
- Fair (neither centralized randomization scheme or study monitor)
- Poor (insufficient documentation of randomization scheme or highly questionable methods)
- Does not apply

Clear Selection

- 3. How appropriate was the control group?
- Excellent (chosen from an appropriate concurrent population of subjects)
- Good (chosen from a concurrent but not ideal population of subjects)
- Fair (chosen from a historical population of subjects)
- Poor (no information given on origin of control group)
- Can't tell
- Does not apply

Clear Selection

- 4. Were the control and treatment groups of enrolled subjects comparable at the beginning of the study?
- Excellent (No significant difference in any characteristic likely to affect success of intervention or other outcome)
- Good (Minor differences in one or more characteristics unlikely to affect success of intervention or other outcome)

Fair (Moderate differences in one or more characteristics which may affect success of intervention or other outcome)

Poor (Major differences in one or more characteristics likely to affect success of intervention or other outcome)

🔵 Can't tell

Does not apply

Clear Selection

5. How well were the inclusion and exclusion criteria for subjects described in the study?

Excellent The inclusion and exclusion criteria were specifically and clearly stated or it was specified that all consecutive subjects were enrolled)

Good (The inclusion and exclusion criteria were stated reasonably completely and clearly, but could have been improved on one or two items)

Fair (The inclusion and exclusion criteria appeared to be lacking in a few items)

Poor (No description of specific inclusion and exclusion criteria)

Can't tell

Clear Selection

6. How well were the characteristics of the study population described?

Excellent (All important subject characteristics are reported, including age, gender, race. For patients, at least one other aspect of socioeconomic status or comorbidities. For providers, specialty and type of practice.)

Ocod (Most of the important subject characteristics are reported, 1-2 missing or characteristics are not classified by subgroup)

Fair (Some of the important subject characteristics are reported, >2 missing. Characteristics may not be classified by subgroup.)

Poor (Few or none of the important subject characteristics are reported. Characteristics may not be classified by subgroup.)

Can't tell

Clear Selection

7. How similar were the sociodemographic and/or clinical characteristics of the subjects who enrolled and the eligible subjects who did not enroll?

Excellent (No significant difference in any characteristic likely to affect success of intervention or other outcome)

Good (Minor differences in one or more characteristics unlikely to affect success of intervention or other outcome)

Fair (Moderate differences in one or more characteristics which may affect success of intervention or other outcome)

Poor (Major differences in one or more characteristics likely to affect success of intervention or other outcome)

Can't tell

Clear Selection

8. Dit the authors specify the reasons that eligible subjects did not enroll specified?

- Yes
- 🔵 No

Not applicable (less than 10% of patients did not enroll)

Don't know who didn't enroll

Clear Selection

STUDY PROTOCOL

9. How well did the authors describe the intervention for changing delivery of the PHE?

Excellent (One could definitely replicate the intervention with the completeness and detail of the description. Or, in the case of a reference description, one could probably replicate the intervention.)

- O Good (One could understand, but not necessarily replicate, the intervention with the detail of the description given.)
- Fair Not nearly enough information about the intervention to fully understand it.)
- Poor (Minimal description of the intervention)

Clear Selection

- 10. How well did the authors describe the PHE?
- Excellent (One could definitely replicate the PHE as described in this study)
- O Good (One could understand, but not necessarily replicate, the PHE as described in this study)
- Fair (Not nearly enough information about the PHE was given for the reader to fully understand what was done)
- Poor (Minimal description of the PHE)

Clear Selection

- 11. Description of intervention referenced?
- Yes
- 🔵 No

Clear Selection

- 12. Were the control and treatment groups treated comparably except for the study intervention(s)?
- Excellent (The groups had no visible differences in the way they were treated)
- Good (The groups had minor differences in treatment unlikely to affect the outcome of the study)
- Fair (The groups had moderate differences in treatment which may affect the outcome of the study)
- Poor (The groups had major differences in treatment likely to affect the outcome of the study)
- Can't tell
- Does not apply

Clear Selection

13. Was there adequate blinding of the target(s) of the intervention to group assignment?

- Yes
- O No
- 🔵 Can't tell
- Not possible given study/intervention
- Does not apply

Clear Selection

14. Was there adequate blinding of the provider(s) of the preventive service to intervention group assignment?

- Yes
- 🔘 No
- 🔵 Can't tell
- Not possible given study/intervention
- O Does not apply

Clear Selection

15. Was there adequate blinding of the assessor(s) of outcomes to group assignments?

Yes

O No

🔵 Can't tell

Does not apply

Clear Selection

16. How were withdrawals (drop-outs while the study was ongoing) or crossovers (subjects who changed from control to intervention group, intervention to control group, or from one intervention to another) handled in the study?

Excellent (Intention to treat and sensitivity analysis are used to examine how results would have differed depending on the inclusion or exclusion of withdrawals or crossovers)

Good (Intention to treat analysis used without sensitivity analysis)

Fair (Withdrawals counted as an end-result at the time of withdrawal, or numbers of cross-overs reported but without intention-to-treat or sensitivity analysis)

Poor (Withdrawals eliminated from study at time of withdrawal or ignored, or cross-overs considered in the new group when they change groups.)

Can't tell

Not applicable (No withdrawals or cross-overs)

Clear Selection

17. How comparable were subjects who withdrew to retained subjects?

Excellent (No significant difference in any characteristic likely to affect success of intervention or other outcome)

O Good (Minor differences in one or more characteristics unlikely to affect success of intervention or other outcome)

Fair (Moderate differences in one or more characteristics which may affect success of intervention or other outcome)

Poor (Major differences in one or more characteristics likely to affect success of intervention or other outcome)

Can't tell

Not applicable

Clear Selection

18. Were withdrawals comparable across intervention groups and across treatment and control arms?

- Yes
- O No
- Can't tell

Not applicable or no withdrawals

Clear Selection

19. Were reasons for withdrawal specified?

Yes

🔵 No

🔵 Can't tell

Not applicable (no withdrawals)

Clear Selection

20. Were relevant and appropriate outcomes measured in this study?

Excellent (The outcomes measured were relevant and were appropriate for the intervention studied. Important, feasible outcomes were measured.)

Good (The outcomes measured were relevant to the preventable condition or to behavior change and were generally appropriate for the intervention studied. Many important, feasible outcomes were measured, but some were clearly lacking.)

Fair (The outcomes measured were relevant to the preventable condition or to behavior change, but lacked appropriateness for the intervention studied.)

Poor (The outcomes measured were only somewhat relevant to the preventable condition or to behavior change.)

Can't tell

Clear Selection

21. Did the length of follow-up for the intervention and frequency of outcome assessments seem appropriate for the outcomes measured?

- Excellent (The length of follow-up and frequency of outcome measurements seemed appropriate.)
- O Good (Either the length of follow-up or the frequency of outcome measurements could have been improved, but both were adequate)
- Fair (Either the length of follow-up or the frequency of outcome measurements was not appropriate)
- Poor (Both the length of follow-up and the frequency of outcome measurements were not appropriate)
- Can't tell

Clear Selection

22. Did the percentage of subjects completing the intervention and evaluation seem appropriate for the main outcomes measured?

- Excellent (The percentage of subjects was desirable for the outcomes measured. Likely >=85%.)
- Good (The percentage of subjects was acceptable for the outcomes measured. Likely 70-84%.)
- Fair (The percentage of subjects is likely lower than needed for at least one of the outcomes measured. Likely 50-69%.)
- Poor (The percentage of subjects is clearly too low for the outcomes measured. Likely less than 50%.)
- Can't tell

Clear Selection

23. Were the outcomes described so that they were understood easily?

- Yes
- 🔵 No

Clear Selection

24. Was assessment of the outcomes standardized and valid?

- Excellent/Good (Both standardized and valid)
- Fair (Standardized or valid, but not both)
- Poor (Neither standardized nor valid)
- Can't tell

Clear Selection

STATISTICAL ANALYSES

25. Were power calculations reported in the study?

A priori estimate (The number of subjects needed to detect a statistically significant difference in the study's outcomes was calculated before the study was conducted.)

Post-hoc estimate (The number of subjects needed was calculated after the study was conducted or at an unspecified time)

No power calculations

Can't tell

Not applicable

Clear Selection

26. How appropriate was the choice of statistical test(s)?

- Excellent (All tests were appropriate for the variables examined and the data distribution. Tests were named for all of the analyses.)
- Good (Most tests were appropriate for the variables examined and the data distribution. Tests were named for most of the analyses.)
- Fair (Some tests were appropriate for the variables examined and the data distribution)
- Poor (Inappropriate statistical tests for the data or no statistical analysis done)
- Can't tell

Clear Selection

27. How was statistical significance presented?

- Confidence limits with or without p-values
- P-values, but not confidence limits
- Neither p-values nor confidence limits
- Other
- Can't tell

Clear Selection

28. Were adjustments made for potential confounders or differences between comparison groups in the study? If potential confounding was present, were adjustments made?

₽

- (Multivariate analysis performed and adequately accounted for potential confounding)
- (Multivariate analysis performed that probably accounted for potential confounding)
- Fair (Multivariate analysis performed that probably did not adequately account for potential confounding)
- Poor (No adjustment made for potential confounding)
- Can't tell
- No confounding present

Clear Selection

29. Were there potential problems with unit of analysis where a prominent outcome of the study involved an endpoint for which providers could not be assumed to be interchangeable, and patients were used as the unit of analysis when physicians should have been used? Were there potential problems with whether the intervention was targeting patients or providers?

- Yes, and the authors accounted for this in their analysis.
- Yes, and the authors acknowledge this in the discussion but not the analysis.
- Yes, and the authors did not account for this in their analysis or discussion.
- O No
- Can't tell
- Does not apply
- **Clear Selection**

Save to finish later Submit Data

Form took 0.46875 seconds to render

Previewing Only: You cannot submit data from this form



Previewing at Level 7

REF ID1Cole, R. C., Morandi, F., Avenell, J., and Daniel, G. B. **Trans-splenic portal scintigraphy in normal dogs** Vet Radiol Ultrasound2005462146-52 State: Excluded, Level: Abstract Review

Save to finish later Submit Data

CHECK ALL OUTCOMES THAT WERE MEASURED IN THIS STUDY CLINICAL PREVENTIVE SERVICES

Physical Exam

	Delivered I	Not deliver	ed		
1. Abdominal	\bigcirc	\bigcirc	Clear		
2. Blood pressure	\bigcirc	\bigcirc	Clear		
3. Breast exam	\bigcirc	\bigcirc	Clear		
4. Cardiac Exam	\bigcirc	\bigcirc	Clear		
5. Eye exam, general	\bigcirc	\bigcirc	Clear		
6. Eye exam, fundiscopic	\bigcirc	\bigcirc	Clear		
7. Gynecologic	\bigcirc	\bigcirc	Clear		
8. Gynecologic, PAP smear	\bigcirc	\bigcirc	Clear		
9. Gynecologic, Pap smear	\bigcirc	\bigcirc	Clear		
10. Height	\bigcirc	\bigcirc	Clear		
11. Neurologic	\bigcirc	\bigcirc	Clear		
12. Prostate	\bigcirc	\bigcirc	Clear		
13. Pulmonary	\bigcirc	\bigcirc	Clear		
14. Pulse	\bigcirc	\bigcirc	Clear		
15. Rectal	\bigcirc	\bigcirc	Clear		
16. Weight	\bigcirc	\bigcirc	Clear		
17. Physical exam not otherwise specified	\bigcirc	\bigcirc	Clear		
Delivered Not delivered	Defi	ne			
18. Other 1			⊮		
19. Other 2			B		
20. Other 3			<u></u>		
Counseling					
Delivered Not delivered	Ł				
21. Alcohol abuse	Clear				
		Deli	vered Not d	elivered	
22. Substance abuse		(\supset	\bigcirc	Clear

23. Calcium intake	\bigcirc	\bigcirc	Clear
24. Diet	\bigcirc	\bigcirc	Clear
25. Firearms	\bigcirc	\bigcirc	Clear
26. Folic acid	\bigcirc	\bigcirc	Clear
27. Injury prevention	\bigcirc	\bigcirc	Clear
28. Oral health	\bigcirc	\bigcirc	Clear
29. Physical activity	\bigcirc	\bigcirc	Clear
30. Polypharmacy	\bigcirc	\bigcirc	Clear
31. Safe sexual practices (my include STD/HIV counseling)	\bigcirc	\bigcirc	Clear
32. Smoking cessation	\bigcirc	\bigcirc	Clear
33. Sun exposure	\bigcirc	\bigcirc	Clear
34. Counseling not otherwise specified	\bigcirc	\bigcirc	Clear
Delivered Not delivered Define			
35. Other 1	B		
36. Other 2	B		

Immunization

37. Other 3

	Delivered I	Not Deliver	ed	
38. Hepatitis B	\bigcirc	\bigcirc	Clear	
39. Influenza	\bigcirc	\bigcirc	Clear	
40. Measles	\bigcirc	\bigcirc	Clear	
41. Mumps	\bigcirc	\bigcirc	Clear	
42. Pneumovax	\bigcirc	\bigcirc	Clear	
43. Rubella	\bigcirc	\bigcirc	Clear	
44. Tetanus	\bigcirc	\bigcirc	Clear	
45. Immunization not otherwise specified	\bigcirc	\bigcirc	Clear	
Delivered Not delivered	De	fine		
46. Other 1			B	
47. Other 2			₽	
48. Other 3			₽	
Testing				
resting				
resting	D	elivered N	ot delivere	d
49. Bone mineral density	D	elivered N	ot delivere	ed Clear
	D	elivered N	ot delivere	-

₽

	\bigcirc	\bigcirc	
52. Colon cancer screening, colonoscopy	\bigcirc	\bigcirc	Clear
53. Colon cancer screening, fecal occult blood test	\bigcirc	\bigcirc	Clear
54. GC/chlamydia	\bigcirc	\bigcirc	Clear
55. Glucose	\bigcirc	\bigcirc	Clear
56. Hemoglobin A1c	\bigcirc	\bigcirc	Clear
57. Mammography	\bigcirc	\bigcirc	Clear
58. PSA	\bigcirc	\bigcirc	Clear
59. Tuberculosis skin test	\bigcirc	\bigcirc	Clear
60. Testing not otherwise specified	\bigcirc	\bigcirc	Clear
Delivered Not delivered De	fine		
61. Other 1		B	
62. Other 2		₽	
63. Other 3		₽	
DISTAL CLINICAL OUTCOME	S, ge	neral	
Applies Does not apply			
64. Death Clear			
65. Hospitalization O Clear			
Applies Does not apply De	fine		
66. Other 1		₽	
67. Other 2		₽	
68. Other 3		₽	
DISTAL CLINICAL OUTCOME	S, Ma	ajor dia	ignostic category



78. Other 1				
79. Other 2			₽	
80. Other 3			₽	
DISTAL ECONOM		COMES	6	
	Applies D	oes not app	ly	
81. Charges	\bigcirc	\bigcirc	Clear	
82. Cost	\bigcirc	\bigcirc	Clear	
83. Disability days	\bigcirc	\bigcirc	Clear	
84. Disease-specific disability d	lays 🔵	\bigcirc	Clear	
85. Work days	\bigcirc	\bigcirc	Clear	
Applies Does not a	ipply	Define		
86. Other 1			₽	

₽

₽

DISEASE DETECTION

87. Other 2

88. Other 3

	Applies Does not apply					
89. Accident	\bigcirc	\bigcirc	Clear			
90. Cardiovascular	\bigcirc	\bigcirc	Clear			
91. Central nervous system	\bigcirc	\bigcirc	Clear			
92. Digestive	\bigcirc	\bigcirc	Clear			
93. Endocrine and metabolic	\bigcirc	\bigcirc	Clear			
94. Mental	\bigcirc	\bigcirc	Clear			
95. Musculoskeletal	\bigcirc	\bigcirc	Clear			
96. Neoplasm	\bigcirc	\bigcirc	Clear			
97. Respiratory	\bigcirc	\bigcirc	Clear			
Applies Does no	ot apply	I	Define			
98. Other 1				3		
99. Other 2				3		
100. Other 3				3		


PROXIMAL CLINICAL OUTCOMES

	Applies	Does not apply	
101. Blood pressure, diastolic or change in DBP	\bigcirc	\bigcirc	Clear
102. Blood pressure, systolic or change in SBP	\bigcirc	\bigcirc	Clear
103. Cholesterol, total	\bigcirc	\bigcirc	Clear

₽ ₽

104. Cholestero	ol, LDL and	triglycerides	6	\bigcirc	\bigcirc	Clear
105. Cholestero	ol, HDL			\bigcirc	\bigcirc	Clear
106. Health stat	tus			\bigcirc	\bigcirc	Clear
107. Hemoglob	in A1c			\bigcirc	\bigcirc	Clear
108. Hypertens	ion			\bigcirc	\bigcirc	Clear
109. Weight cha	ange			\bigcirc	\bigcirc	Clear
Ap	oplies Doe	s not apply		Define		
110. Other 1					₽	
111. Other 2					₽	
112. Other 3					₽	

BEHAVIORAL OUTCOMES



PATIENT ATTITUDES

	Applies [Does not app	ply		
120. Knowledge	e 🔘	\bigcirc	Clear		
121. Respect	\bigcirc	\bigcirc	Clear		
122. Satisfaction	n 🔵	\bigcirc	Clear		
Ap	plies Does	not apply		Define	
123. Other 1					₽
124. Other 2					₽
125. Other 3					₽

PUBLIC HEALTH

	Applies Does	s not apply	Define	
126. Other 1			5	,
127. Other 2			B	,
128. Other 3				•

If outcomes for any of the following categories have been identifed please proceed to the outcome specific forms for THIS article: Delivery of Preventive Clinical Services, Distal Clinical Outcomes, Distal Economic Outcomes, Disease Detection

******	****************************

AUDITOR INFORMATION

this section IS NOT to be completed by reviewer #1

129. Auditor information		
Auditor Name	0.	
Auditor review completion date	100 M	
130. Auditor Notes		
Enlarge Shrink		
Save to finish later Submit Data		

Form took 1.71875 seconds to render

🖨 🔸 🗲 🔚

Previewing Only: You cannot submit data from this form

Previewing at Level 8

Refid: 1, Cole, R. C., Morandi, F., Avenell, J., and Daniel, G. B., Trans-splenic portal scintigraphy in normal dogs, Vet Radiol Ultrasound, 46(2), 2005, p.146-52 State: Excluded, Level: 2

Save to finish later Submit Data

1. OUTCOME #1:

Define outcomes in order they are identified in previous questions on this form.

Enlarge Shrink 2. Who assessed OUTCOME 1? check all that apply
Practicing Health Provider
Community health worker
3. Is OUTCOME 1 self-reported?
◯ Yes-physician
O Yes-patient
No
Not applicable
Clear Selection 4. Are the results for OUTCOME 1 adjusted for potential confounding factors?
Ves
No
Not applicable
Clear Selection 5. OUTCOME 1 Adjusted for (check all that apply)
Age
Sex
Race
Insurance
Education
Comorbid disease
Medication use
Practice mix
Provider experience
Body mass index
Weight
Smoking
Lipids
Blood pressure
Diabetes
Not Specified
Other
Other
Other 🚱
Not applicable
6. Does OUTCOME 1 apply to the target patient population or providers?

Patient	
Physician	
Both	
Clear Selection	

7. OUTCOME 1

Target PATIENT Population GROUP number (use group # as assigned in the General Abstraction form)



8. OUTCOME 1

Target PROVIDER Population GROUP number (use group # as assigned in the General Abstraction form)



Specify units for OUTCOME 1

Absolute number	
Diagnoses	
mmHg	
mg/dl	
pounds	
kilograms	
percentage	
dollars	
cost effectiveness ratio	₽
Other	₽
Other	₽
Other	
no units specified	
no applicable	
10. Was there a reference/comparision group for this stu	udy?
Yes	
No	

Clear Selection

For each PATIENT group complete all that apply for OUTCOME 1

Sample size

	Patient group 1	Patient group 2	Patient group 3	Patient group 4	Patient group 5
11. Baseline n	₽	₽	₽	₽	₽
12. Follow-up n	B	₽	<u></u>	G	B

Absolute result

Absolute res	ult				
	Patient group 1	Patient group 2	Patient group 3	Patient group 4	Patient group 5
13. Baseline	₽	₽	₽	₽	₽
14. Follow-up	B	B	₽	⊡ ≁	<u></u>
15. Change	B	₽	₽	₽	<u></u>
Mean, baseli	ne				
	Patient group 1	Patient group 2	Patient group 3	Patient group 4	Patient group 5
16. Mean	₽	₽	₽	₽	₽
	Patient group 1	Patient group 2	Patient group 3	Patient group 4	Patient group 5
17. Standard error of mean		·	- anon gion, o	- antin group -	B
18. Standard	B	₽	B	B	B
deviation					
19. Variance	B	₽	B	B	₽
Mean, follow	-up				
	Patient group 1	Patient group 2	Patient group 3	Patient group 4	Patient group 5
20. Mean	5	₽	B	1	₽
21. Standard	Patient group 1	Patient group 2	Patient group 3	Patient group 4	Patient group 5
error of mean	₽	<u> </u>	9	₽	⊡ ≁
22. Standard deviation	<u></u>	<u></u>	₽	₽	₽
23. Variance	₽	₽	₽	₽	6
Mean, chang	e				
	Patient group 1	Patient group 2	Patient group 3	Patient group 4	Patient group 5
24. Mean					- unit group o
I	Patient group 1	Patient group 2	Patient group 3	Patient group 4	Patient group 5
25. Standard error of mean	P diterit group P	i diisin group 2	P dilotit glodp 0	P duorn group P	
26. Standard	Gr		0.		3
deviation		57 10	6	97 13	-
27. Variance	B	B	6	<u></u>	B
Median, base	eline				
	Patient group 1	Patient group 2	Patient group 3	Patient group 4	Patient group 5
28. Median	<u></u>	B	B	6	3
	Patient group 1	Patient group 2	Patient group 3	Patient group 4	Patient group 5
29. Standard error	<u>_</u>	<u></u>	B	₽	6
30. Standard deviation	₽	₽	₽	₽	6
31. Variance	<u></u>	₽	6	B	6
Median, follo	an-ma				
,	Patient group 1	Patient group 2	Patient group 3	Patient group 4	Patient group 5
32. Median	₽	₽	₽	B	₽
	Patient group 1	Patient group 2	Patient group 3	Patient group 4	Patient group 5
33. Standard					
error 34. Standard	U		C	D	₽ ₽
deviation					
35. Variance	₽	₽	B	B	⊡ -
Median, chai	nge				
	Patient group 1	Patient group 2	Patient group 3	Patient group 4	Patient group 5
36. Median	₽	B	₽	6	₽
	Patient group 1	Patient group 2	Patient group 3	Patient group 4	Patient group 5
37. Standard error	₽	B	9	₽	9

38. Standard deviation	۵	}	₽		₽		B		₽
39. Variance		}	₽		₽		₽		₽
Correlation co	pefficient								
	Patient group 1	Patient group	2	Patient group 3		Patient group 4		Patient group 5	
40. Measured coefficient	t	3	₽		₽		₽		₽
Odds Ratio									
	Patient group 1	Patient group 2		Patient group 3		Patient group 4		Patient group 5	
41. Odds ratio	•	r	₽	6	3-	(3		₽
	Patient group 1	Patient group	2	Patient group 3		Patient group 4		Patient group 5	
42. Mark reference group	C.	3	₽		3		₽		₽
43. 95% Cl upper/lower	C	3	₽		₽		₽		₽
Relative Risk									
	Patient group 1	Patient group	2	Patient group 3		Patient group 4		Patient group 5	
44. Relative risk	[3	₽		₽		₽		₽
	Patient group 1	Patient group 2	2	Patient group 3		Patient group 4		Patient group 5	
45. Mark reference group		}	₽		₽		₽		₽
46. 95% Cl upper/lower		}	B		₽		₽		₽
Hazard Ratio									
	Patient group 1	Patient group	2	Patient group 3		Patient group 4		Patient group 5	
47. Hazard ratio	[3	₽		B		₽		B
	Patient group 1	Patient group	2	Patient group 3		Patient group 4		Patient group 5	
48. Mark reference group	0	3	₽		P		B		P
49. 95% Cl upper/lower	t	3	₽		₽		₽		₽

For each PROVIDER group complete all that apply for OUTCOME 1

Sample size					
P	rovider group 1	Provider group 2	Provider group 3	Provider group 4	Provider group 5
50. <i>n</i>	⊡ ≁	B	⊡ ≁	B	₽
Absolute res	sult				
	Provider group 1	Provider group 2	Provider group 3	Provider group 4	Provider group 5
51. Baseline	₽	₽		₽	₽ ₽
52. Follow-up	₽	B		₽	₽ ₽
53. Change	G-	B		₽	₿ ₿
Mean, basel	ine				
	Provider group 1	Provider group 2	Provider group 3	Provider group 4	Provider group 5
54. Mean	₽	B	₽	6	₽ B
	Provider group 1	Provider group 2	Provider group 3	Provider group	4 Provider group 5
55. Standard error of mean	B	9	•	₽	₿ ₿
56. Standard deviation	6	9	•	B	B B
57. Variance	₽	B		₽	₿ ₽
Mean, follow	/-up				
	Provider group 1	Provider group 2	Provider group 3	Provider group 4	Provider group 5
58. Mean	₿-	B	G	6	3 D

https://www.clinical-analytics.com/d2d/ul1/review.asp?mode=previewMode&articleid=637&level=8

	Provider group 1		Provider group 2		Provider group 3		Provider group 4	Provider group 5	
59. Standard error of mean	5 - 5 - 5	₽		₽		₽	I	• •	4
60. Standard deviation		₽		₽		₽		-	3
61. Variance		2		₽		-		-	3
lean, change	1					-			
	Provider group 1		Provider group 2		Provider group 3		Provider group 4	Provider group 5	
62. Mean	⊡		3		₽ ₽		⊡	6	
	Provider group 1		Provider group 2		Provider group 3		Provider group 4	Provider group 5	
63. Standard error of mean	5 - 5 - 5	₽		₽		₽	I		3
64. Standard		₽		•		₽		-	4
65. Variance		-		2		₽			V
/ledian, basel	ine								
iculari, basci	Provider group 1		Provider group 2		Provider group 3		Provider group 4	Provider group 5	
66. Median									}
	Provider group 1		Provider group 2		Provider group 3		Provider group 4	Provider group 5	
67. Standard	r tovider group i	₽	r tovider group 2	₽	Fronder group 3	₽	Provider group 4	. .	4
error of mean 68. Standard		3		₽		3			
deviation		6		3			0		_
69. Variance		2		2		₽			M
ledian, follow	•				.				
0. Median	Provider group 1		Provider group 2		Provider group 3		Provider group 4	Provider group 5	L
or modian	Provider group 1		Provider group 2		Provider group 3		Provider group 4	Provider group 5	
1. Standard		₽		₽		₽			1
error of mean 72. Standard		•				3			
deviation 73. Variance		6 7		5 5		₽ ₽			
		5		5		5		r	2
/ledian, chang			5						
74. Median	Provider group 1		Provider group 2		Provider group 3	_	Provider group 4	Provider group 5	L
in modulari			1 -					-	
75. Standard	Provider group 1	₽	Provider group 2	•	Provider group 3	₽	Provider group 4	Provider group 5	
error of mean 76. Standard		5		5- 12-		₽ ₽	3		
deviation				-					2
7. Variance		₽		₽		₽	5	r	M
Correlation co	Provider group 1		Provider group 2		Provider group 3		Provider group 4	Provider group 5	
78. Measured	Flovider group 1	₽	Flovider group 2	₽	Flovider group 3	₽		• ·	6
Ddds Ratio		-							_
	Provider group 1		Provider group 2		Provider group 3		Provider group 4	Provider group 5	
9. Odds ratio		₽		₽		P			3
	Provider group 1		Provider group 2		Provider group 3		Provider group 4	Provider group 5	
30. Mark eference	- · ·	₽	- ·	₽	. .	₽	с . []		4
group 31. 95% Cl									
upper/lower		₽		₽		₽		r	V
Relative Risk									
	Provider group 1		Provider group 2		Provider group 3		Provider group 4	Provider group 5	
82. Relative risk		₽		₽		₽	5	8	

	Provider group 1	Provider group 2		Provider group 3		Provider group 4		Provider group 5			
83. Mark reference group	3		₽		₽		₽		₽		
84. 95% Cl upper/lower	9		₽		₽		₽		₽		
Hazard Ratio											
	Provider group 1	Provider group 2		Provider group 3		Provider group 4		Provider group 5			
85. Hazard ratio	6		₽		3		₽		₽		
	Provider group 1	Provider group 2		Provider group 3		Provider group 4		Provider group 5			
86. Mark reference group	G		B		₽		₽		₽		
87. 95% Cl upper/lower	5		₽		₽		₽		₽		
			AUDITOR	INFORMATION							
this section IS NOT to be completed by reviewer #1											

88. Auditor information				
Auditor Name	₽			
Auditor review completion date	⊡ -	₿ ²		
89. Auditor Notes				
Enlarge Shrink				
Save to finish later Su	bmit Data			

Form took 2.578125 seconds to render